CTOs on the Move

Establishment Labs

www.establishmentlabs.com

 
Establishment Labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. With more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for Establishment Labs` founders and top executives. As a result, Motiva Implants® has established a level of product innovation that always results in safety. And while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Establishment Labs raised $55M on 08/28/2017

Similar Companies

U-Metco

U-Metco is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oliver-Tolas Healthcare Packaging

Oliver-Tolas Healthcare Packaging is one of the world's leading producers of sterile-grade medical device packaging and pharmaceutical packaging. Oliver-Tolas brings together the best of Oliver Medical Packaging and Tolas Healthcare Packaging's 30+ years producing the industry's highest quality and most innovative products.

PLANMECA USA

PLANMECA USA is a Roselle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Technology Wristbands

Medical Technology Wristbands is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tearlab

TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.